• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Travere Therapeutics Inc. (Amendment)

    2/14/24 6:38:50 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVTX alert in real time by email
    SC 13G/A 1 d724312dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Travere Therapeutics Inc

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    89422G107

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 89422G107

     

     1.   

     Names of Reporting Persons

     

     Macquarie Group Limited

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Sydney, New South Wales Australia

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,746,144 deemed beneficially owned due to reporting person’s ownership of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust whose individual holdings are shown on the following forms.

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     6.31%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC

     

    Page 2 of 13


    CUSIP No. 89422G107

     

     1.   

     Names of Reporting Persons

     

     Macquarie Management Holdings Inc

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     State of Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     4,746,144

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     4,746,144

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,746,144 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Business Trust

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☒

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     6.31%

    12.  

     Type of Reporting Person (See Instructions)

     

     HC

     

    Page 3 of 13


    CUSIP No. 89422G107

     

     1.   

     Names of Reporting Persons

     

     Macquarie Investment Management Business Trust

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     State of Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     4,746,144

       6.   

     Shared Voting Power

     

     0

       7.   

     Sole Dispositive Power

     

     4,746,144

       8.   

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,746,144

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☒

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     6.31%

    12.  

     Type of Reporting Person (See Instructions)

     

     IA

     

    Page 4 of 13


    Item 1.

      

    (a)

      

    Name of Issuer

     

    Travere Therapeutics Inc

      

    (b)

      

    Address of Issuer’s Principal Executive Offices

     

    3611 Valley Centre Drive, Suite 300, San Diego, CA 92130

    Item 2.

       (a)   

    Name of Person Filing

     

    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc and Macquarie Investment Management Business Trust

       (b)   

    Address of Principal Business Office or, if none, Residence

     

    The principal business address of Macquarie Group Limited is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 610 Market Street, Philadelphia, PA 19106.

       (c)   

    Citizenship

     

    Macquarie Group Limited - Sydney, New South Wales, Australia Corporation

    Macquarie Management Holdings Inc., Macquarie Investment Management Business Trust– incorporated or formed under the laws of the State of Delaware.

       (d)   

    Title of Class of Securities

     

    Common Stock

       (e)   

    CUSIP Number

     

    89422G107

    Item 3.

      

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

       (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       (k)    ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Page 5 of 13


    Item 4.    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a)   

    Amount beneficially owned:

     

    See responses on the cover page hereto.

       (b)   

    Percent of class:

     

    See responses on the cover page hereto.

       (c)    Number of shares as to which the person has:
          (i)   

    Sole power to vote or to direct the vote

     

    See responses on the cover page hereto.

          (ii)   

    Shared power to vote or to direct the vote

     

    0

          (iii)   

    Sole power to dispose or to direct the disposition of

     

    See responses on the cover page hereto.

          (iv)   

    Shared power to dispose or to direct the disposition of

     

    0

    Item 5.    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    See Exhibit A.
    Item 8.    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.    Notice of Dissolution of Group
    Not applicable.

     

    Page 6 of 13


    Item 10.

      

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited       February 14, 2024
          Date
    /s/ Philip Alexander       /s/ Charles Glorioso
    Signature       Signature
             

    Philip Alexander

    Associate Director

         

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Management Holdings, Inc.       February 14, 2024
          Date
    /s/ Marty Wolin      
    Signature      
           

    Marty Wolin

    Chief Compliance Officer

         

     

    Macquarie Investment Management Business Trust       February 14, 2024
          Date
    /s/ Marty Wolin      
    Signature      
           

    Marty Wolin

    Chief Compliance Officer

         

     

    Page 7 of 13

    Get the next $TVTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVTX

    DatePrice TargetRatingAnalyst
    10/31/2025$34.00 → $48.00Buy
    Citigroup
    6/11/2025$30.00Buy
    H.C. Wainwright
    6/11/2025$35.00 → $32.00Buy
    Citigroup
    1/10/2025Overweight
    Cantor Fitzgerald
    10/21/2024$9.00 → $27.00Equal Weight → Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$25.00Neutral → Buy
    Guggenheim
    3/27/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $TVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Cline Christopher R. sold $56,168 worth of shares (1,745 units at $32.19), decreasing direct ownership by 2% to 111,226 units (SEC Form 4)

    4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

    2/5/26 4:05:23 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Inrig Jula sold $57,295 worth of shares (1,779 units at $32.21), decreasing direct ownership by 2% to 105,706 units (SEC Form 4)

    4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

    2/5/26 4:05:25 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer and GC Reed Elizabeth E sold $96,359 worth of shares (2,994 units at $32.18), decreasing direct ownership by 3% to 105,211 units (SEC Form 4)

    4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

    2/5/26 4:05:13 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 49,200 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the gran

    2/11/26 5:00:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is

    2/4/26 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

    New PDUFA target action date is April 13, 2026 Commercial launch preparations continue in anticipation of potential approval Travere Therapeutics, Inc., (NASDAQ:TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026. The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit of FILSPARI. The FDA determined that the additional responses constituted a Major Amendment (MA) to

    1/13/26 1:24:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Travere Therapeutics Inc.

    SCHEDULE 13G - Travere Therapeutics, Inc. (0001438533) (Subject)

    2/9/26 8:10:02 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Travere Therapeutics Inc.

    144 - Travere Therapeutics, Inc. (0001438533) (Subject)

    2/4/26 4:07:29 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Travere Therapeutics Inc.

    144 - Travere Therapeutics, Inc. (0001438533) (Subject)

    2/3/26 9:59:44 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup reiterated coverage on Travere Therapeutics with a new price target

    Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $48.00 from $34.00 previously

    10/31/25 10:57:06 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Travere Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Travere Therapeutics with a rating of Buy and set a new price target of $30.00

    6/11/25 7:55:49 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup reiterated coverage on Travere Therapeutics with a new price target

    Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $32.00 from $35.00 previously

    6/11/25 7:31:38 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

    SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

    11/14/24 5:13:38 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Travere Therapeutics Inc.

    SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)

    11/14/24 1:01:01 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

    SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

    11/14/24 9:46:28 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVTX
    Financials

    Live finance-specific insights

    View All

    Travere Therapeutics Reports Third Quarter 2025 Financial Results

    U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including U.S. net product sales of $113.2 million Retired remaining $69 million of 2025 convertible notes and achieved $40 million EU market access milestone, further strengthening financial foundation 2025 KDIGO guidelines and streamlined REMS monitoring strengthen FILSPARI's position as a foundational, nephroprotective therapy for IgAN Company well-positioned for potential FDA approval and commercial launch of FILSPARI for FSGS in 1Q26 Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported

    10/30/25 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics to Report Third Quarter 2025 Financial Results

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical

    10/23/25 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics Reports Second Quarter 2025 Financial Results

    U.S. net product sales of FILSPARI® (sparsentan) grew 165% year-over-year to $71.9 million in 2Q 2025; 745 new PSFs received in the quarter sNDA seeking full approval of FILSPARI for FSGS accepted for review; PDUFA target action date set for January 13, 2026 Total revenue for 2Q 2025 was $114.4 million, including net product sales of $94.8 million Cash, cash equivalents, and marketable securities totaled approximately $319.5 million as of June 30, 2025 Travere Therapeutics, Inc., (NASDAQ:TVTX) today reported its second quarter 2025 financial results and provided a corporate update. "We continue to make strong progress against our strategic priorities, putting Travere on a trajecto

    8/6/25 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVTX
    Leadership Updates

    Live Leadership Updates

    View All

    Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

    Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm

    7/11/22 8:00:00 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

    Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

    3/23/22 7:30:00 AM ET
    $ATRA
    $NTRA
    $TVTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations

    Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

    SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics

    1/4/22 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care